BIOKÉ Webshop

Forgot password?Login

No account?

Enjoy the advantages of a BIOKÉ webshop account.

Invalid login

Your credentials are incorrect or you are trying to login with a non-existing webshop account. Our website shows product prices without login! Therefore webshop accounts that were only used to view prices have been deleted.

Please create a new account with your shipping and billing details if you would like to be able to order or view your discount.

Webshop under construction

Due to technical maintenance the webshop is closed until January 3, 2024. We wish you a successful 2024!

Forgot your password?

Don't worry. Enter your username and we will send you a link to reset your password if an associated user is found.

Need help?

Have trouble resetting your password? Contact us and we will help you.

You've got mail

You will receive an e-mail containing a link to start the recovery procedure within minutes.

Change password

Change your password to something secure.


Your password has been changed.

Password sent

You will receive an e-mail from us containing your new password in the coming minutes.

Please change your password to something memorable and secure upon logging in.


Sign out

Cell Signaling Technology Licenses PTMScan to Genentech to Enable Discovery Proteomics Research


DANVERS, MA (PRWEB) – September 28, 2018 Cell Signaling Technology (CST) a leading provider of antibodies, kits, and services, announced that Genentech, a member of the Roche Group, has licensed proprietary PTMScan® technology from CST, further enabling discovery proteomics research.

The CST PTMScan technology is an immuno-affinity enrichment method that allows for the discovery of hundreds to thousands of novel sites of post-translational modifications (PTMs), including phosphorylation and ubiquitination. By combining the specificity of biomedical techniques with the dynamic range of proteomics methods, PTMScan provides a more focused approach to peptide enrichment compared to other strategies. Genentech currently utilizes PTMScan methodology to investigate and publish on a range of scientific research in multiple therapeutic areas.

“CST is pleased to have licensed PTMScan to Genentech to further enable their world-class discovery and drug development research while expanding the impact of PTMScan immuno-affinity enrichment technology. PTMScan is a powerful technology that can be leveraged to answer a variety of biological questions,” said Roberto Polakiewicz, Ph.D. Cell Signaling Technology, Chief Scientific Officer.

For more information about the application of PTMScan methodology in discovery proteomics research via profiling of post-translational modifications, please visit the webinar section of the CST’s proteomics web


About CST PTMScan Technology

PTMScan® technology is a proprietary proteomic method that combines antibody enrichment of PTM containing peptides with liquid chromatography mass spectrometry (LC-MS/MS). PTMScan technology allows identification and quantification of hundreds to thousands of even the lowest abundance peptides and provides a more focused approach to peptide enrichment than other strategies. For licensing inquiries, email [email protected]


About CST

Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.


Cell Signaling Technology®, PTMScan®, and CST™ are trademarks of Cell Signaling Technology, Inc.

Product has been added to your cart.